

# Supplementary Document S1: Structured interview

## Baseline questionnaire – 2019

---

### ***Sociodemographic***

**Birth date:** \_\_\_\_\_years

**Sex:**    ☐ female  
            ☐ male

**Partnership status:**    ☐ single living  
                                  ☐ partnership

**Current job situation:**

☐ in training  
☐ studies  
☐ employment: ☐ full-time                      ☐ part-time  
☐ unemployment  
☐ pension:                      ☐ due to old age                      ☐ due to disability  
☐ other

**School years (at most until A-levels):** \_\_\_\_\_years

**Educational level:**    ☐ no training  
                                  ☐ skilled worker  
                                  ☐ technical college  
                                  ☐ university

**Place of residence:**

---

☐ rural community (until 5000 inhabitants)  
☐ provincial town (>5000-20000 inhabitants)  
☐ medium-sized town (>20000-100000 inhabitants)  
☐ city (>100000 inhabitants)

**Number of children:** \_\_\_\_\_

**Number of siblings:** \_\_\_\_\_

---

**Clinical-neurological**

**Current pregnancy:**    ☐ no  
                                     ☐ yes

**Pregnancy planned in the near future:**    ☐ no  
   ☐ yes

**Number and kind of comorbidities:**

**Disease course:**    ☐ clinically isolated syndrome (CIS)  
                                 ☐ relapsing-remitting multiple sclerosis (RRMS)  
                                 ☐ secondary progressive multiple sclerosis (SPMS)  
                                 ☐ primary progressive multiple sclerosis (PPMS)  
                                 ☐ undefined

**Clinical care:**    ☐ outpatient  
                             ☐ inpatient

**Date of initial CIS/MS diagnosis (month/year):** \_\_\_\_\_

**Current Expanded Disability Status Scale (EDSS) Score:** \_\_\_\_\_

---

## Medication

### Use of disease-modifying drugs (DMD)

	Currently	Previously	Never	Unknown
Interferon beta (Avonex, Rebif, Plegridy, Betaferon, Extavia)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Glatiramer acetate (Copaxone)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Teriflunomide (Aubagio)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Fingolimod (Gilenya)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Dimethyl fumarate (Tecfidera)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Mitoxantrone (Novantron, Ralenova)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Natalizumab (Tysabri)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Alemtuzumab (Lemtrada)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Daclizumab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Ocrelizumab (Ocrevus)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cladribine (Mavenclad)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Intravenous immunoglobulin G (Octagam)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Azathioprine (AZA-effect, Aza-Q, Azafalk, Azaimun, Azamedac, Imurek, Imurel)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cyclophosphamide	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cyclic glucocorticosteroids (Urbason)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

### Reason for DMD switch:

- ☐ Side effects
- ☐ Disease activity despite DMD treatment
- ☐ Pregnancy
- ☐ Personal
- ☐ Other

**Medication schedule**

	Preparation	Drug	Indication	Dosage	Intake interval	Route of administration	Prescription status	Therapy goal (DMD, symptom treatment, treatment of comorbidities or other conditions)
1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
13								
14								
15								
16								
17								
18								
19								
20								